Research Article

A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma

Volume: 15 Number: 1 March 9, 2021
TR EN

A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma

Abstract

Objective: Obesity is an important health concern all around the world and considered in relation to a number of comorbidities. In this study, we aimed to evaluate the incidence of renal angiomyolipoma (AML) in obese patients. Method: This retrospective study included 288 obese patients, who were followed up at the Obesity Center of the University of Health Sciences, Antalya Training and Research Hospital between 01/11/2018 and 01/02/2020. The laboratory parameters and the reports of the abdominal ultrasound scans (USG) taken when the patients first presented to our unit were all reviewed. The patients were divided into two groups: those with and without renal AML based on the abdominal USG reports, and were compared in terms of serum hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), erythrocyte count (RBC), blood urea nitrogen (BUN), creatinine and uric acid levels. Results: Of the patients, 93.05% were female and 6.94% were male. The mean age was 51.91±9.31 (21-73) years, the average body mass index (BMI) was 36.4 (30-65.19) kg/m2. Ten patients (3.47%) had renal AML found on the abdominal USG imaging reports. While the incidence of renal AML in the general population is reported to be 0.13%-0.44%, it was found 3.47% in our study with obese patients. Conclusion:The incidence of renal AML is increasing in obese patients. Associated with many comorbidities, obesity may also constitute a risk factor for renal AML. In order to determine the relationship between obesity and AML, more studies are needed with multi-centered and broader scopes.

Keywords

Supporting Institution

There is no support.

Thanks

We would like to thank Başak OĞUZ YOLCULAR for all the support she provided in the statistical analysis process of this study.

References

  1. 1. Kıyan E. Obezite ve akciğer. Türkiye Klinikleri Göğüs Hastalıkları-Özel Konular 2020; 13 (1), 94-98.
  2. 2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism Clinical and Experimental 2019; 92: 6-10.
  3. 3. Türkiye Endokrinoloji ve Metabolizma Derneği Obezite tanı ve tedavi kılavuzu 2019. Available online at http://temd.org.tr/admin/uploads/tbl_kilavuz/ 20190506163904- 2019tbl_kilavuz5ccdcb9e5d.pdf. Accessed June 8, 2020.
  4. 4. Dixon JB. The effect of obesity on health outcomes. Molecular and cellular endocrinology, 2010; 316 (2), 104-108.
  5. 5. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity, 2020; 28 (7), 1200-1204.
  6. 6. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. Journal of the National Cancer Institute, 2015; 107 (2), 1-14.
  7. 7. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology, 2015; 16 (1), 36-46.
  8. 8. World Cancer Research Fund. Continuous Update Project Expert Report 2018. Available online at http://dietandcancerreport.org. Accessed July 8, 2020.

Details

Primary Language

English

Subjects

​Internal Diseases

Journal Section

Research Article

Publication Date

March 9, 2021

Submission Date

September 28, 2020

Acceptance Date

December 18, 2020

Published in Issue

Year 2021 Volume: 15 Number: 1

APA
Bulca Acar, A., & Nur Eke, R. (2021). A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. Turkish Journal of Family Medicine and Primary Care, 15(1), 136-141. https://doi.org/10.21763/tjfmpc.800756
AMA
1.Bulca Acar A, Nur Eke R. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 2021;15(1):136-141. doi:10.21763/tjfmpc.800756
Chicago
Bulca Acar, Aysima, and Remziye Nur Eke. 2021. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care 15 (1): 136-41. https://doi.org/10.21763/tjfmpc.800756.
EndNote
Bulca Acar A, Nur Eke R (March 1, 2021) A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. Turkish Journal of Family Medicine and Primary Care 15 1 136–141.
IEEE
[1]A. Bulca Acar and R. Nur Eke, “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”, TJFMPC, vol. 15, no. 1, pp. 136–141, Mar. 2021, doi: 10.21763/tjfmpc.800756.
ISNAD
Bulca Acar, Aysima - Nur Eke, Remziye. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care 15/1 (March 1, 2021): 136-141. https://doi.org/10.21763/tjfmpc.800756.
JAMA
1.Bulca Acar A, Nur Eke R. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 2021;15:136–141.
MLA
Bulca Acar, Aysima, and Remziye Nur Eke. “A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma”. Turkish Journal of Family Medicine and Primary Care, vol. 15, no. 1, Mar. 2021, pp. 136-41, doi:10.21763/tjfmpc.800756.
Vancouver
1.Aysima Bulca Acar, Remziye Nur Eke. A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma. TJFMPC. 2021 Mar. 1;15(1):136-41. doi:10.21763/tjfmpc.800756

English or Turkish manuscripts from authors with new knowledge to contribute to understanding and improving health and primary care are welcome. 


Turkish Journal of Family Medicine and Primary Care © 2024 by Academy of Family Medicine Association is licensed under CC BY-NC-ND 4.0